Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7231 to 7245 of 7675 results

  1. RapidAI for analysing CT/MRI brain scans in people with suspected acute stroke (MIB262)

    This medtech innovation briefing has been updated and replaced by diagnostics guidance on artificial intelligence (AI)-derived software to help clinical decision making in stroke (DG57).

    Medtech innovation briefing
    Published
    1 June 2021

  2. Therapeutic hypothermia following cardiac arrest (IPG386)

    This guidance has been updated and replaced by NICE interventional procedures guidance 782.

    Interventional procedures guidance
    Published
    23 March 2011

  3. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    14 June 2018

  4. Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.  

    Evidence summary
    Published
    13 November 2017

  5. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

    Evidence summary
    Published
    6 June 2017

  6. Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

    In development [GID-TA10935] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Sepsis (QS161)

    February 2024: We have temporarily withdrawn this quality standard due to ongoing updates to the NICE guideline on sepsis, which underpins the quality statements. See the guidance in development page and guideline in development page for progress on these updates.

    For any queries, please contact qualitystandards@nice.org.uk

    Quality standard
    Last updated
    18 June 2020

  8. Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

    In development [GID-TA10800] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

    Discontinued [GID-IPG10142]

    Interventional procedures guidance
    Discontinued

  10. COVID-19 rapid guideline: severe asthma (NG166)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.

    COVID-19 rapid guideline
    Published
    3 April 2020

  11. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development [GID-TA11070] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Health technology evaluations: interim methods and process guide for the proportionate approach to technology appraisals (PMG40)

    This interim methods and process guide for the proportionate approach to technology appraisals has been incorporated into NICE health technology evaluations: the manual.

  13. Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) (TA700)

    This guidance has been updated and replaced by NICE technology appraisal guidance 970 and NICE technology appraisal guidance 974.  

    Technology appraisal guidance
    Published
    19 May 2021

  14. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)

    This guidance has been updated and replaced by NICE technology appraisal guidance 975.  

    Technology appraisal guidance
    Published
    21 December 2018

  15. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development [GID-TA11253] Expected publication date: TBC

    Technology appraisal guidance
    In development